Toxicology Drug Screening Global Market Report 2025

The toxicology drug screening market size has grown strongly in recent years. It will grow from $19.56 billion in 2024 to $21.44 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The historical growth is driven by increasing instances of drug misuse, the introduction of workplace drug testing regulations, a rise in toxicology testing in athletic settings, the expansion of forensic toxicology capabilities, and the growing use of toxicology analysis in criminal investigations.

The toxicology drug screening market size is expected to see strong growth in the next few years. It will grow to $30.67 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. Contributing factors to this future growth include the surge in personalized medicine approaches, heightened regulatory emphasis on drug safety, an uptick in the usage of cannabis and synthetic substances, broader healthcare infrastructure development in developing countries, and the increasing prevalence of substance abuse. Key trends projected during this period involve innovations in high-throughput screening tools, enhanced use of artificial intelligence in toxicology analytics, the emergence of point-of-care toxicology diagnostics, progress in biomarker-driven screening techniques, and improved automation and robotic systems in drug screening workflows.

The increasing prevalence of drug abuse is anticipated to drive the growth of the toxicology drug screening market. Drug abuse refers to the harmful or excessive consumption of drugs for non-medical purposes, which adversely affects an individual's health and well-being. The rise in drug abuse is attributed to growing stress and mental health issues, prompting many to use substances as a coping mechanism. Toxicology drug screening plays a crucial role in detecting the presence of drugs or their metabolites in the body, facilitating early identification, diagnosis, and monitoring of substance misuse or overdose. For example, in August 2024, the National Records of Scotland (NRS), a government department in Scotland, reported 1,172 drug misuse deaths in 2023, reflecting a 12% increase (121 additional deaths) compared to 2022. As a result, the rising incidence of drug abuse is contributing to the expansion of the toxicology drug screening market.

Leading companies in the toxicology drug screening market are introducing innovative solutions such as forensic toxicology screening to improve the accuracy and speed of substance detection in clinical, forensic, and workplace environments. Forensic toxicology screening involves the examination of biological samples to identify drugs, poisons, or toxins associated with criminal investigations, accidents, or fatalities. For instance, in June 2022, Thermo Fisher Scientific Inc., a US-based biotechnology and life sciences firm, launched the ToxSpec Analyzer, a comprehensive LC-MS (liquid chromatography-mass spectrometry) system designed for clinical and forensic toxicology applications. This solution combines hardware, software, and validated methods to automate and optimize drug analyte screening, making the technology accessible even to labs with limited experience in LC-MS/MS. The ToxSpec Analyzer enhances operational efficiency, boosts identification accuracy, and allows laboratories to add new compounds as needed.

In September 2024, Scantox Group, a preclinical contract research organization based in Denmark that specializes in toxicology testing, acquired Gentronix for an undisclosed sum. The acquisition is intended to strengthen Scantox Group's early toxicity testing capabilities by incorporating Gentronix's expertise in genetic toxicology and predictive safety evaluation, thereby broadening its services for the pharmaceutical and chemical sectors. Gentronix, headquartered in the UK, is a preclinical contract research organization offering toxicology services, including drug screening.

Major players in the toxicology drug screening market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, BD Bioscience, Quest Diagnostics, ICON plc, Agilent Technologies Inc., Eurofins Scientific SE, Wuxi AppTec, Charles River Laboratories International Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Evotec AG, Promega Corporation, The Jackson Laboratory, Clinical Reference Laboratory Inc., Enzo Life Sciences Inc., Covance Inc., Randox Toxicology, and Alere Inc.

North America was the largest region in the toxicology drug screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in toxicology drug screening report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the toxicology drug screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Toxicology drug screening is a process designed to detect drugs, chemicals, or their metabolites in biological samples such as urine, blood, saliva, or hair. This type of medical testing is frequently utilized to identify both legal and illegal substances present in a person's system. Its primary purpose is to determine and assess drug exposure in an individual, serving a variety of needs depending on the application context.

Toxicology drug screening encompasses several major types, including monitoring and logging, security, storage, continuous integration or deployment, management and orchestration, networking, data management services, and others. Monitoring and logging refer to the ongoing tracking and documentation of data derived from tests and related activities. This category involves multiple test types such as acute systemic toxicity, dermal toxicity, carcinogenicity, ocular toxicity, genotoxicity, neurotoxicity, and organ-specific toxicity. It also incorporates advanced technologies like high-throughput screening, genomics, transcriptomics, toxicogenomics, and molecular screening. Applications include immunotoxicity, systemic toxicity, developmental and reproductive toxicity (DART), endocrine disruption, among others. The end users of these screenings span across hospitals, clinics, contract research organizations (CROs), pharmaceutical firms, and workplace drug testing centers.

The toxicology drug screening market research report is one of a series of new reports that provides toxicology drug screening market statistics, including toxicology drug screening industry global market size, regional shares, competitors with a toxicology drug screening market share, detailed toxicology drug screening market segments, market trends and opportunities, and any further data you may need to thrive in the toxicology drug screening industry. This toxicology drug screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The toxicology drug screening market consists of revenues earned by entities by providing services, such as pre-employment drug testing, sports drug testing, confirmatory testing, addiction treatment monitoring, and pain management monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.